Search research articles
Contact Us
Filters
Showing results (111-120 of 137) with videos related to
Page
of 14
Sort By:
Oncoimmunology
|
May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Cancer Cell
|
May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Yared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.
JAMA Oncology
|
April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial
Guo Chen, Jennifer L McQuade, David J Panka, et al.
Cancer Cell
|
September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell
|
December 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Nature Communications
|
July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications
|
April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Cancer Discovery
|
April 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study
Salah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, et al.
Nature Medicine
|
March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 137) with videos related to
Sort By:
Page
of 14
Oncoimmunology
|
May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Cancer Cell
|
May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Yared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.
JAMA Oncology
|
April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial
Guo Chen, Jennifer L McQuade, David J Panka, et al.
Cancer Cell
|
September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell
|
December 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Nature Communications
|
July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications
|
April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Cancer Discovery
|
April 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study
Salah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, et al.
Nature Medicine
|
March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Page
of 14